Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAA05 in Recurrent/Refractory AML
NCT05017883Phase 2Recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jul 2021
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAA05 in acute myeloid leukemia (AML), sponsored by PersonGen BioTherapeutics. Primary endpoint: Objective Response Rate at 3 months. Started Jul 2021; status: recruiting.
02
Drugs
TAA05
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05017883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017883.